Accessibility Menu
Novozymes A/s logo

Novozymes A/s(OTC) NVZMY

Market Cap$27.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)+1,815%
5 Year-9%
1 Year+2%
1 Month+1%
$65.64
+2.26%
+1.45Today
Novozymes A/s last closing stock price
MetricPriceDate
Last closeUSD 65.642026-08-14
Novozymes A/s stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.5%USD 65.972026-08-07
1 month+1.19%USD 64.872026-07-15
3 month+12.03%USD 58.592026-05-15
Year to date+4.39%USD 62.882025-12-31
1 year+2.37%USD 64.122025-08-14
3 year+50.24%USD 43.692023-08-15
5 year-9%USD 72.132021-08-13
Since inception+1,815.36%USD 3.432003-02-24

Novozymes A/s Financials at a Glance

Market Cap

$27.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€3.33B

Net Income (TTM)

-€407.07M

EPS (TTM)

$1.48

P/E Ratio

44.18

Dividend

$1.00

Beta (Volatility)

0.47 (Low)

Price

$65.64

Volume

53,744

Open

$65.70

Previous Close

$65.64

Daily Range

$64.91 - $65.85

52-Week Range

$49.90 - $66.66

Estimated Earnings Date

Aug 20, 2026

NVZMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Novozymes A/s

Novozymes A/S is a global biotechnology firm specializing in the creation and distribution of industrial enzymes, microorganisms, and probiotics. With a strong operational footprint across multiple regions, Novozymes serves various sectors, including food and beverages, agriculture, and household care.

Products and Services
  • Industrial enzymes for food processing and agriculture
  • Microorganisms for bioenergy and waste management
  • Probiotics for human health and animal nutrition
Growth Outlook
  • Revenue growth of 14% year-over-year in Q1 2026
  • Strong demand in agriculture and bioenergy sectors
  • Investment in R&D to drive innovation and market expansion
Financial Highlights
  • Net income of €202 million in Q1 2026, reflecting a 17.8% margin
  • Trailing twelve-month revenue of €4.5 billion, indicating robust performance
  • Dividend yield of 1.58%, showcasing commitment to shareholder returns
Novozymes A/S has established itself as a leader in the biotechnology sector, focusing on sustainable solutions that cater to diverse industries. The company's innovative products not only enhance efficiency but also contribute to environmental sustainability. Recent financial performance highlights a strong revenue growth trajectory, particularly in the first quarter of 2026, driven by increased demand in key sectors. The commitment to research and development positions Novozymes favorably for future growth, making it an attractive option for investors interested in the biotechnology and sustainability space.
AI Generated • Jul 25, 2026

Industry

Chemicals

Sector

Materials

Employees

11,641

CEO

Ester Baiget, MBA

Website

www.novonesis.com

Headquarters

Lyngby, ND 2880, DK

NVZMY Financials

Key Financial Metrics (TTM)

Gross Margin

54.33%

Operating Margin

20.85%

Net Income Margin

14.21%

Return on Equity

5.52%

Return on Capital

2.65%

Return on Assets

3.61%

Earnings Yield

2.26%

Dividend Yield

1.53%

Payout Ratio

1.12%

Stock Overview

Market Cap

$27.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

412.49M

Volume

53.74K

Avg. Volume

38.19K

Financials (TTM)

Gross Profit

€1.82B

Operating Income

€723.21M

EBITDA

€1.06B

Operating Cash Flow

€4.28B

Capital Expenditure

-€1.10B

Free Cash Flow

€3.17B

Cash & ST Invst.

€329.74M

Total Debt

€3.22B

Novozymes A/s Performance Analysis

Novozymes A/s annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 2,479,729,1234.4%
20232023-12-31EUR 2,597,085,2684.7%
20242024-12-31EUR 4,146,660,60159.7%
20252025-12-31EUR 4,692,176,29913.2%
Novozymes A/s sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-5.4%
Q32025-09-30677.2%
Q42025-12-31-6.1%
Q12026-03-3114.2%
Novozymes A/s annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 1.864.4%
20232023-12-31EUR 1.58-15.2%
20242024-12-31EUR 0.72-54.4%
20252025-12-31EUR 1.4195.7%
Novozymes A/s sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-27.4%
Q32025-09-30671.2%
Q42025-12-31-13.3%
Q12026-03-3165.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

€1.14B

+688.1%

Gross Profit

€644.63M

+709.6%

Gross Margin

56.66%

N/A

Market Cap

$27.08BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.33M

N/A

Employees

11,641

N/A

Net Income

€202.37M

+712.1%

EBITDA

€424.98M

+1050.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

€329.74M

+28.6%

Total Debt

€3.22B

+89.3%

Accounts Receivable

€924.56M

+5.3%

Inventory

€793.53M

+8.7%

Long Term Debt

€2.93B

+130.6%

Short Term Debt

€289.40M

-32.7%

Return on Assets

3.61%

N/A

Return on Invested Capital

5.72%

N/A

Free Cash Flow

€89.45M

+74.7%

Operating Cash Flow

€169.85M

+59.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
EMSHFEms-Chemie Holding AG
$979.75-0.00%
AKZOYAkzo Nobel N.V.
$24.08+0.25%
GVDNYGivaudan S.A.
$80.46+0.32%
SXYAYSika AG
$23.46-0.17%

Trending Stocks

Symbol / CompanyPricePrice Chg
NUNu Holdings
$15.23+0.09%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.76+0.01%
ONDSOndas
$9.24+0.04%
SPCXSpace Exploration Technologies
$140.00-0.01%

Questions About NVZMY

What is the current price of Novozymes A/s?

Novozymes A/s is trading at $65.64 per share.

What is the 52-week range for Novozymes A/s?

Over the past 52 weeks, Novozymes A/s has traded between $49.90 and $66.66.

How much debt does Novozymes A/s have?

As of the most recent reporting period, Novozymes A/s reported total debt of €3.70B.

How much cash does Novozymes A/s have on hand?

Novozymes A/s reported €377.00M in cash and cash equivalents in its most recent financial results.

What is Novozymes A/s’s dividend yield?

Novozymes A/s currently has a dividend yield of 1.53%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services